[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:poorly-differentiated-carcinoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":15,"states":16},"Poorly differentiated carcinoma",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07163273","Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma",[11],"Phase 2","RECRUITING","2026-08-26T02:17:56.243868Z","2026-04-29T02:57:57.072540Z",[],[]]